Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elevance HealthELV +3.05%90 EV-to-EBITDA is 11.96 as of Aug. 05, 2026, which is 1% above its 10-year median of 11.79. GuruFocus rates ELV with a GF Score™ of 90/100 and a GF Value™ of $489.98 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 15 Healthcare Plans companies, Elevance Health ranks better than 60% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elevance Health's enterprise value is $105,428 Mil.
Elevance Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $8,813 Mil. Therefore, Elevance Health's EV-to-EBITDA for today is 11.96.
The historical rank and industry rank for Elevance Health's EV-to-EBITDA or its related term are showing as below:
ELV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.63 Med: 11.79 Max: 15.38
Current: 11.96
During the past 13 years, the highest EV-to-EBITDA of Elevance Health was 15.38. The lowest was 7.63. And the median was 11.79.
ELV's EV-to-EBITDA is ranked better than 60% of 15
companies
in the Healthcare Plans industry
Industry Median: 13.89
vs ELV: 11.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Elevance Health (NYSE:ELV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elevance Health's PE Ratio (TTM) for today is calculated as:
Elevance Health's share price for today is $389.53.
Elevance Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Elevance Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, Elevance Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elevance Health EV-to-EBITDA vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Elevance Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elevance Health's EV-to-EBITDA falls into.
Elevance Health's current Enterprise Value is $105,428 Mil.
Elevance Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,813 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elevance Health (ELV) has a EV-to-EBITDA of 11.96 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elevance Health. This is near median its historical median of 11.79. Over the past decade, Elevance Health's EV-to-EBITDA has ranged from 7.63 to 15.38. According to the industry distribution chart, Elevance Health ranks #6 out of 15 companies in the Healthcare Plans industry, placing it in the top 40%.
Is Elevance Health's EV-to-EBITDA too high?
Elevance Health's current EV-to-EBITDA of 11.96 is near median its 10-year median of 11.79. Over the past 10 years, this metric has ranged from a low of 7.63 to a high of 15.38. The Healthcare Plans industry median EV-to-EBITDA is 13.89. Elevance Health's value of 11.96 is 13.9% below this industry median. Based on the distribution chart, Elevance Health ranks #6 out of 15 companies in the Healthcare Plans industry, which is above the industry midpoint. Overall, Elevance Health has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's EV-to-EBITDA compare to CI and HUM?
According to the Healthcare Plans industry distribution chart, Elevance Health ranks #6 out of 15 companies for EV-to-EBITDA. This puts Elevance Health in the upper half of its industry. The industry median EV-to-EBITDA is 13.89. Elevance Health's value of 11.96 is 13.9% below this benchmark. Historically, Elevance Health's own EV-to-EBITDA has ranged from 7.63 to 15.38 over the past decade. While the company's 10-year median is 11.79 vs. the industry median of 13.89, Elevance Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Plans company?
The median EV-to-EBITDA among Healthcare Plans companies is 13.89, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elevance Health's current EV-to-EBITDA of 11.96 is 13.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elevance Health. For the Healthcare Plans industry, the median EV-to-EBITDA is 13.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elevance Health's current EV-to-EBITDA is 11.96, which is near median its own 10-year median of 11.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (ELV) is currently considered Modestly Undervalued. The stock's GF Value™ is $489.98, compared to a current price of $389.53 — trading 20.5% below its estimated fair value. The current EV-to-EBITDA is 11.96, which is near median its 10-year median of 11.79 and 13.9% below the Healthcare Plans industry median of 13.89. Elevance Health's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elevance Health (ELV), the current EV-to-EBITDA is 11.96 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elevance Health (ELV) Overvalued in 2026?
Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued.
The current stock price of $389.53 is trading 20.5% below its estimated GF Value™ of $489.98.
GuruFocus considers Elevance Health to be Modestly Undervalued.
Key valuation signals for ELV:
EV-to-EBITDA: 11.96 (near median its 10-year median of 11.79)
GF Value™: $489.98 vs. price of $389.53 (20.5% below fair value)
Industry Position: 13.9% below the Healthcare Plans median (#6 of 15)
No single metric tells the full story. See the ELV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
90GF Score
Get the complete analysis for ELV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELV has been successfully added to your 
